期刊
JCI INSIGHT
卷 2, 期 14, 页码 -出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/jci.insight.93751
关键词
-
资金
- NIH NEI [EY022383, EY022683]
- Fight for Sight (UK)
- Sir Jules Thorn Trust
- DEL/SFI
- Wolfson Foundation
- Royal Society
- NIH NEI R01 [EY024702]
- JDRF [3-SRA-2014-264-M-R]
- Massachusetts Lions Eye Research Fund
- MRC [G0801962, MC_PC_16083, G0600053] Funding Source: UKRI
- Fight for Sight [1891/92, 1871/72, 1315/16] Funding Source: researchfish
- Medical Research Council [G0801962, G0600053, MC_PC_16083] Funding Source: researchfish
- The Sir Jules Thorn Charitable Trust [10JTA] Funding Source: researchfish
Diabetic retinopathy (DR) causes significant visual loss on a global scale. Treatments for the vision-threatening complications of diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) have greatly improved over the past decade. However, additional therapeutic options are needed that take into account pathology associated with vascular, glial, and neuronal components of the diabetic retina. Recent work indicates that diabetes markedly impacts the retinal neurovascular unit and its interdependent vascular, neuronal, glial, and immune cells. This knowledge is leading to identification of new targets and therapeutic strategies for preventing or reversing retinal neuronal dysfunction, vascular leakage, ischemia, and pathologic angiogenesis. These advances, together with approaches embracing the potential of preventative or regenerative medicine, could provide the means to better manage DR, including treatment at earlier stages and more precise tailoring of treatments based on individual patient variations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据